BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 87.26% | 85.05% | 74.03% | 93.09% | 84.79% |
| Total Depreciation and Amortization | -88.95% | -21.71% | 32.08% | 66.07% | 201.28% |
| Total Amortization of Deferred Charges | 5.66% | 14.41% | 14.41% | 2,347.46% | 1,157.63% |
| Total Other Non-Cash Items | 46.59% | -98.50% | -1,268.44% | -254.88% | -182.01% |
| Change in Net Operating Assets | 105.77% | 111.49% | -18.43% | -378.18% | -243.55% |
| Cash from Operations | 81.60% | 55.46% | 30.13% | -12.73% | -94.06% |
| Capital Expenditure | 52.83% | 108.00% | 107.89% | 81.90% | 54.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -128.95% | 239.94% | 215.33% | -60.96% | 1,786.35% |
| Cash from Investing | -129.09% | 235.40% | 214.47% | -60.75% | 1,934.21% |
| Total Debt Issued | -- | -100.00% | -100.00% | -- | -- |
| Total Debt Repaid | 66.47% | -328.21% | -333.56% | -439.96% | -651.71% |
| Issuance of Common Stock | -16.09% | 36.99% | 8.58% | 59.92% | -2.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -56.99% | -73.06% | -77.17% | 118.15% | 37.21% |
| Foreign Exchange rate Adjustments | 2,395.45% | 1,026.92% | 687.13% | -48.00% | 109.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -216.26% | -183.14% | -406.03% | 199.02% | 197.62% |